Literature DB >> 8653931

Topic and systemic administration of natural alfa interferon in the treatment of female and male HPV genital infections.

P Stentella1, A Frega, F Di Renzi, P L Palazzetti, A Pachì.   

Abstract

The aim of the study was to evaluate the effectiveness and tolerance of topic and systemic administration of natural alfa-interferon from normal human leukocytes in the treatment of HPV lesions of the lower genital tract. From May 1991 through May 1992, 70 women (mean age = 29; range 16-42) and 51 men (mean age = 28; range 18-48) with histologically proven HPV genital lesions were studied. 43 patients and 32 male partners with subclinical infection underwent cream therapy (4 applications/day for 30 days) composed of natural alfa interferon and containing 1,000,000 IU/gr. 27 women and 19 men affected by florid infection underwent systemic i.m. therapy with natural alfa interferon in doses of 3,000,000 IU on alternate days for 30 days. The percentage of therapeutical success amounted to 55.8% for women and 78.1% for men subjected to topic therapy; for the 27 patients and 19 male partners treated with systemic therapy the final percentages of success were 70.3% respectively. Natural alfa interferon from normal human leucocytes seems to be a drug of good efficacy and tolerance in the treatment of HPV genital pathology.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8653931

Source DB:  PubMed          Journal:  Clin Exp Obstet Gynecol        ISSN: 0390-6663            Impact factor:   0.146


  2 in total

1.  Insights into the Role of Innate Immunity in Cervicovaginal Papillomavirus Infection from Studies Using Gene-Deficient Mice.

Authors:  Carolina Scagnolari; Fabiana Cannella; Alessandra Pierangeli; Rebecca Mellinger Pilgrim; Guido Antonelli; Dayana Rowley; Margaret Wong; Simon Best; Deyin Xing; Richard B S Roden; Raphael Viscidi
Journal:  J Virol       Date:  2020-06-01       Impact factor: 5.103

Review 2.  Antiviral therapy: respiratory infections, chronic hepatitis.

Authors:  B I Asmar; N M Abdel-Haq
Journal:  Indian J Pediatr       Date:  2001-07       Impact factor: 5.319

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.